Late Tuesday, Gilead said the companies wouldn't seek regulatory approval for a drug known as filgotinib in rheumatoid arthritis treatment in … +0.23 (+0.34%) CLOSED AT 4:00 PM ET ON May 12, 2021. The firm owned 37,051 shares of the biopharmaceutical company’s stock after purchasing an additional 1,388 shares during the period. Gilead Sciences News: Die neuesten Meldungen zur Gilead Sciences Aktie im Überblick – alle aktuellen Nachrichten, Analysen, Überblicke rund um Gilead Sciences. Gilead Sciences pays an annual dividend of $2.84 per share and currently has a dividend yield of 4.27%. Other Gilead Stock News On Aug. 19, GILD stock fell 4.9% after the company announced the FDA's unexpected decision to seek two more years … Gilead Sciences at … Gilead Sciences (885823 | US3755581036) mit aktuellem Aktienkurs, Charts, News und Analysen. Gilead Sciences news and GILD price. Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with … May 30, 2020 12:37 AM IST US pharma … On average, they expect Gilead Sciences' share price to reach $100.59 in the next year. Gilead Sciences (GILD) cut its losses on a rheumatoid arthritis treatment in partnership with Galapagos (GLPG), sending GLPG stock tumbling on Wednesday. Jun 1, 2021 at 1:30 PM EDT. This suggests a possible upside of 52.2% from the stock's current price. Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD Gilead Sciences Statement on Recent Events in Washington, D.C. Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP® Gilead Sciences Inc. [NASDAQ: GILD] closed the trading session at $67.42 on 06/07/21. The company’s stock price has collected 0.32% of gains in the last five trading TOKYO, Apr 23, 2021 - (JCN Newswire) - Gilead Sciences K.K. Für Gilead Sciences liegt der Umfang der Anleger-Diskussionen aktuell bei 570 Prozent. Distributed by Public, unedited and … Gilead Sciences Inc (NASDAQ: GILD) reported lower than expected Q1 earnings with EPS of $2.08, slightly below the analyst consensus estimate of $2.09 but higher than $1.68 last year. Gilead Sciences The company report on June 4, 2021 that Kite’s Tecartus® Demonstrates High Response Rate in Adults With Relapsed or … Mirador Capital Partners LP’s holdings in Gilead Sciences … Gilead Sciences (NASDAQ:GILD) is scheduled to announce Q3 earnings results on Wednesday, October 28th, after market close. gilead sciences Latest Breaking News, Pictures, Videos, and Special Reports from The Economic Times. Gilead Sciences News: Die neuesten Meldungen zur Gilead Sciences Aktie im Überblick – alle aktuellen Nachrichten, Analysen, Überblicke rund um Gilead Sciences… Jun 2, 2021 at 4:30 PM EDT. Gilead's antisense intellectual property portfolio was sold to Ionis Pharmaceuticals. Gilead Sciences Inc. (NASDAQ:GILD) went down by -0.87% from its latest closing price compared to the recent 1-year high of $79.31. Gilead Sciences Announces 4.4 Percent Increase in First Quarter 2021 Dividend February 04, 2021 Gilead Sciences Announces Fourth Quarter and Full Year 2020 Financial Results February 02 appears to be modestly undervalued, according to GuruFocus Value calculation. Mirador Capital Partners LP boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.9% during the 1st quarter, according to its most recent filing with the SEC. Mirador Capital Partners LP’s holdings in Gilead Sciences were worth … Shares of Gilead surged as much as 11% in early trading Wednesday after the company said a leading coronavirus treatment succeeded in a critical trial. 1 month ago - Zacks Investment Research Why Gilead (GILD) Could Beat Earnings Estimates Again The company report on June 4, 2021 that Kite’s Tecartus® Demonstrates High Response Rate in Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Earning Priority Review Designation. Gilead reported $478 million in revenue from Descovy, down 6% Q/Q. Gilead Sciences CEO Daniel O'Day told CNBC on Monday the company is testing remdesivir to determine whether it is effective in treating new coronavirus strains that emerged in the U.K. and South Africa. Gilead Sciences (NASDAQ:GILD) Stock Rating Reaffirmed by Jefferies Financial Group. Britain's AstraZeneca has approached U.S. rival Gilead Sciences about a possible merger to form one the world's largest drug companies, Bloomberg News reported on … Gilead reported $478 million in revenue from Descovy, down 6% … BACK TO MAIN MENU Company Statements Gilead Statement on New England Journal of Medicine Publication of Positive Phase 3 ASCENT Study of Trodelvy in Metastatic Triple-Negative Breast Cancer Gilead Sciences … Jun 1, 2021 at 1:30 PM EDT. Gilead debuted on the NASDAQ in January 1992. Gilead Sciences Announces Second Quarter 2021 Dividend Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors … Kite's Tecartus® Demonstrates High Response Rate in Adults With Relapsed or The company report on May 20, 2021 that Gilead-Kite Oncology to Present Transformative Gilead Sciences (GILD) closed at $66.38 in the latest trading session, marking a +0.65% move from the prior day. Zuletzt wies die Gilead Sciences-Aktie Gewinne aus. For the fiscal year 2017, Gilead Sciences reported earnings of US$4.628 billion and annual revenue of US$26.107 billion, a decline of 14.1% over the previous fiscal cycle. The company report on May 20, 2021 that Gilead-Kite Oncology to Present Transformative Shares of the big biotech have instead jumped 20% so far this year, putting Gilead in an elite group of stocks in positive territory in 2020. Events. Gilead Sciences News: Die neuesten Meldungen zur Gilead Sciences Aktie im Überblick – alle aktuellen Nachrichten, Analysen, Überblicke rund um Gilead Sciences… Stock analysis for Gilead Sciences Inc (GILD:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Gilead Sciences at Goldman Sachs Annual Global Healthcare Conference. News zur GILEAD SCIENCES AKTIE und aktueller Realtime-Aktienkurs Gilead's Trodelvy New Subgroup Data Shows Benefit in Second-Line Breast Cancer Patients Anzeige ETHealthworld.com brings latest gilead sciences news, views and updates from all top sources for the Indian Health industry. Dr. Pedersen states that GS-441524 is safe and … msn.com - May 28 at 10:54 AM. Boston Beer (SAM) Gains But Lags Market: What You Should Know Zacks 28 Apr, 2021, 08.36 AM IST. Gilead Sciences Inc. published this content on 08 April 2021 and is solely responsible for the information contained therein. The company could soon enter yet another major market. Gilead Sciences, Inc. (Nasdaq: GILD) and MYR GmbH, a German biotechnology company focused on the development and commercialization of therapeutics for … Free real-time prices, trades, and chat. Events. Gilead Sciences Inc. (NASDAQ:GILD) went down by -0.87% from its latest closing price compared to the recent 1-year high of $79.31. Its initial public offering raised $86.25 million in proceeds. Gilead Sciences Inc. (NASDAQ:GILD) went up by 1.43% from its latest closing price compared to the recent 1-year high of $79.31. Get Gilead Sciences Inc (GILD:NASDAQ) real-time stock quotes, news, price and financial information from FintechZoom. Gilead Sciences news and GILD price. Kaufen, halten oder verkaufen – Ihre Biogen-Analyse vom 08.06. Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest health-care deal on record. The company’s stock price has collected 1.01% of gains in the last five trading Gilead Sciences is about to announce its earnings — here's what to expect Markets Insider Automation 40d Gilead to donate 450,000 doses of COVID-19 drug to India Date Time Source Heading 5/19/2021 17:00 BW Gilead-Kite Oncology to Present Transformative Science From.. 5/18/2021 16:08 SEEK marketbeat.com - May 7 at 12:18 PM. Their forecasts range from $61.00 to $625.00. View the latest Gilead Sciences Inc. (GILD) stock price, news, historical charts, analyst ratings and financial information from WSJ. Free real-time prices, trades, and chat. Gilead Sciences reports earnings Thursday. Nasdaq 100. In Zusammenarbeit mit www.sharewise.com biete ich bekanntlich regelmäßig meine Video-Wunschanalyse an. Find the latest Gilead Sciences, Inc. (GILD) stock quote, history, news and other vital information to help you with your stock trading and investing. Russian court rejects U.S firm's lawsuit over COVID-19 drug remdesivir. For more information about Gilead, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD … marketbeat.com - May 7 at 12:18 PM. News Gilead Sciences had roots in NC well before Tuesday’s big jobs announcement – here’s a look gilead sciences Gilead's HQ (Gilead photo) by … GILD | Complete Gilead Sciences Inc. stock news by MarketWatch. US drugmaker Gilead Sciences on Tuesday donated 450,000 vials of the Covid-19 drug remdesivir to India, even as the delayed supplies from its manufacturing partners, including Sun Pharma, Zydus Cadila, Cipla and Biocon, have led to a shortage of the anti-Covid drug in the … Jun 2, 2021 at 4:30 PM EDT. 1 month ago - Zacks Investment Research Why Gilead (GILD) Could Beat Earnings Estimates Again GILD: Get the latest Gilead Sciences stock price and detailed information including GILD news, historical charts and realtime prices. Die Aktie von Gilead Sciences gehört zu den Performance-Besten des Tages. Gilead Sciences Inc (NASDAQ: GILD) reported lower than expected Q1 earnings with EPS of $2.08, slightly below the analyst consensus estimate of $2.09 but higher than $1.68 last year. Gilead Sciences (NASDAQ:GILD) Stock Rating Reaffirmed by Jefferies Financial Group. Gilead Sciences company Kite has announced results from the primary analysis of ZUMA-5, a Phase II study… ASH Biotechnology Conferences Drug Trial Gilead Sciences Hematology Kite Kite Pharma Oncology Research USA Gilead Sciences, Inc. announced today that Anthony Welters has been appointed to the company’s Board of Directors. News zur GILEAD SCIENCES AKTIE und aktueller Realtime-Aktienkurs … • Black-market sellers rely on the perception that their substance is safe and effective to convince buyers to disregard the illegal/stolen property/unregulated part. Für Gilead Sciences liegt der Umfang der Anleger-Diskussionen aktuell bei 570 Prozent. Gilead Sciences (NASDAQ:GILD) isn't one of them. Gilead Sciences Inc. [NASDAQ: GILD] closed the trading session at $67.42 on 06/07/21. 21 analysts have issued 1-year target prices for Gilead Sciences' shares. Gilead Sciences (885823 | US3755581036) mit aktuellem Aktienkurs, Charts, News und Analysen. Gilead Sciences : Statement on New England Journal of Medicine Publication of Positive Phase 3 ASCENT Study of Trodelvy in Metastatic Triple-Negative Breast Cancer Foster City, Calif., April 21, 2021 - Gilead Sciences issued the following statement from Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences… Distributed by Public, unedited and unaltered, on 08 April 2021 15:09:04 UTC. Gilead currently pays a quarterly dividend of $0.71, which is higher than the $0.68 it was paying last year. Short term disappointing news from great businesses can create spectacular long-term opportunities for investors. The company could soon enter yet another major market. Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest health-care deal on record. In Zusammenarbeit mit www.sharewise.com biete ich bekanntlich regelmäßig meine Video-Wunschanalyse an. The company’s stock price has collected 2.32% of gains in the last five trading Russian court rejects U.S firm's lawsuit over COVID-19 drug remdesivir. Gilead Sciences reports earnings Thursday. Its lead candidate is entospletinib, a SYK inhibitor acquired as part of a deal with Gilead Sciences last month, under development for patients with … 4:00a Barron's What's Driving the … GILD has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. Gilead Sciences is not only grossly undervalued compared to … Die Aktie notiert derzeit mit 67.45 USD beinahe unverändert (+0.04 Prozent). In Brief This Week: Gilead Sciences, Atossa Therapeutics, Karmanos Cancer Institute | Precision Oncology News Gilead Sciences Inc. [NASDAQ: GILD] closed the trading session at $67.42 on 06/07/21. (GILD) Nasdaq Listed. Gilead Sciences-Aktie über 20-Tage-Linie Mit dem Anstieg auf 55,50 EUR hat die Gilead Sciences-Aktie am 07.06.2021 die 20-Tage-Linie nach oben gekreuzt.Die Gilead Sciences-Aktie … Gilead Sciences (885823 | US3755581036) mit aktuellem Aktienkurs, Charts, News und Analysen. Gilead Sciences, Inc. (Nasdaq: GILD) and MYR GmbH, a German biotechnology company focused on the development and commercialization of therapeutics for Gilead … Their forecasts range from $61.00 to $625.00. The 1-year high price for the company’s stock is recorded $70.11 on 05/21/21, with the lowest value was $57.93 for the same time Gilead Sciences, Inc. Common Stock (GILD) Gilead Sciences, Inc. Common Stock. CSR and Sustainability news for Gilead Sciences, Inc., Biotechnology and USA. Zum … The company’s stock price has collected 2.32% of gains in the last five trading Gilead Sciences Inc. (NASDAQ:GILD) went down by -0.87% from its latest closing price compared to the recent 1-year high of $79.31. $67.45. and Eisai Co., Ltd. today announced that Gilead submitted an application to Japan's … Gilead Sciences Inc. published this content on 08 April 2021 and is solely responsible for the information contained therein. Data is … On average, they expect Gilead Sciences' share price to reach $100.59 in the next year. Jun 9, 2021 at 2:10 PM EDT. [citation needed] In June 1996, Gilead launched Vistide (cidofovir injection) for the treatment of cytomegalovirus (CMV) reti… Date Time Source Heading 5/19/2021 17:00 BW Gilead-Kite Oncology to Present Transformative Science From.. 5/18/2021 16:08 SEEK Environment 59 Employees 60 Community 59 Governance 53. Find the latest dividend history for Gilead Sciences, Inc. Common Stock (GILD) at Nasdaq.com. The day’s price range saw the stock hit a low of $67.11, while the highest price level was $67.9644. Gilead Sciences Statement on the Passing of the Honorable George P. Shultz, PhD Gilead Sciences Statement on Recent Events in Washington, D.C. Gilead Announces New Arm of HIV Women’s Prevention Study to Evaluate the Investigational Long-Acting HIV-1 Capsid Inhibitor Lenacapavir in Addition to Descovy for PrEP® msn.com - May 28 at 10:54 AM. Gilead Sciences (GILD) closed at $67.43 in the latest trading session, marking a +1.43% move from the prior day. Boston Beer (SAM) Gains But Lags Market: What You Should Know Zacks Mirador Capital Partners LP boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.9% during the 1st quarter, according to its most recent filing with the SEC. This suggests a possible upside of 52.2% from the stock's current price. Gilead Sciences, Inc. Common Stock (GILD) Gilead Sciences, Inc. Common Stock. The stock is up 13.3% YTD and is currently trading at forward earnings of 9.9x. Here's a core earnings analysis. The company report on May 20, 2021 that Gilead-Kite Oncology to Present Transformative Gilead Sciences' experimental drug Remdesivir has been found to aid in the recovery of COVID-19 patients. CSR and Sustainability news for Gilead Sciences, Inc., Biotechnology and USA. GILD | Complete Gilead Sciences Inc. stock news by MarketWatch. WHO defends data after concluding Gilead's remdesivir flopped Covid-19 trial $67.45. Zuletzt wies die Gilead Sciences-Aktie Gewinne aus. The company’s stock price has collected 2.32% of gains in the last five trading View real-time stock prices and stock quotes for a full financial overview. Gilead Sciences Announces 4.4 Percent Increase in First Quarter 2021 Dividend February 04, 2021 Gilead Sciences Announces Fourth Quarter and Full Year 2020 Financial Results February 02 Gilead Sciences : Kite's Tecartus Demonstrates High Response Rate in Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Earning Priority Review Designation SANTA MONICA, Calif. - Kite, a Gilead Company (Nasdaq: GILD), announced results from the primary analysis of ZUMA-3, a global, multicenter, single-arm, open-label Phase 1/2 study evaluating its … The company’s stock price has collected 0.32% of gains in the last five trading Gilead's acquisition of Kite Pharma in 2017 immediately launched the big biotech into a top spot in the CAR-T cancer cell therapy market. Gilead Sciences (NASDAQ:GILD) is scheduled to announce Q3 earnings results on Wednesday, October 28th, after market close. Gilead Sciences' experimental drug Remdesivir has been found to aid in the recovery of COVID-19 patients. Gilead Sciences Inc. [NASDAQ: GILD] loss -0.87% on the last trading session, reaching $68.75 price per share at the time. Fauci on remdesivir drug study for COVID-19 05:28 Wall Street on Wednesday cheered another round of positive news on Gilead Sciences' experimental drug remdesivir, which the … Gilead Sciences Description Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. View real-time stock prices and stock quotes for a full financial overview. Its lead candidate is entospletinib, a SYK inhibitor acquired as part of a deal with Gilead Sciences last month, under development for patients with biomarker-defined acute myeloid leukemia. Gilead Sciences (GILD) closed at $66.38 in the latest trading session, marking a +0.65% move from the prior day. Gilead Sciences (NASDAQ:GILD) isn't one of them. Environment 59 Employees 60 Community 59 Governance 53. +0.23 (+0.34%) CLOSED AT 4:00 PM ET ON May 12, 2021. Gilead's acquisition of Kite Pharma in 2017 immediately launched the big biotech into a top spot in the CAR-T cancer cell therapy market. In der XETRA-Sitzung ging es … Nachrichten zur GILEAD SCIENCES Aktie - schnell & kompetent - Aktuelle TOP-Meldung: Gilead Sciences hat die … The firm owned 37,051 shares of the biopharmaceutical company’s stock after purchasing an additional 1,388 shares during the period. The company’s stock price has collected 0.32% of gains in the last five trading Headline. ETHealthworld.com brings latest gilead sciences news, views and updates from all top sources for the Indian Health industry. Gilead Sciences's shares traded at over $70 per share Stock analysis for Gilead Sciences Inc (GILD:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Die Aktie von Gilead Sciences gehört zu den Performance-Besten des Tages. The day’s price range saw the stock hit a low of $67.11, while the highest price level was $67.9644. GuruFocus Article or News written by GF Value and the topic is about: The stock of Gilead Sciences (NAS:GILD, 30-year Financials) appears to be modestly undervalued, according to GuruFocus Value calculation.) 21 analysts have issued 1-year target prices for Gilead Sciences' shares. (Head office: Chiyoda-ku, Tokyo; President and Representative Director: Luc Hermans; “Gilead”) and Eisai Co., Ltd. (Head office: Bunkyo-ku, Tokyo, CEO: Haruo Naito; “Eisai”) today announced that Gilead submitted an application to Japan’s Pharmaceuticals and Medical … Gilead Sciences (GILD) closed at $67.43 in the latest trading session, marking a +1.43% move from the prior day. Find the latest Gilead Sciences, Inc. (GILD) stock quote, history, news and other vital information to help you with your stock trading and investing. Kaufen, halten oder verkaufen – Ihre Biogen-Analyse vom 08.06. GuruFocus Article or News written by GF Value and the topic is about: The stock of Gilead Sciences (NAS:GILD, 30-year Financials) appears to be modestly undervalued, according to GuruFocus Value calculation.) Gilead Sciences Inc. (NASDAQ:GILD) went up by 1.43% from its latest closing price compared to the recent 1-year high of $79.31. Here's a core earnings analysis. Gilead Sciences at Bernstein Annual Strategic Decisions Conference. News items for the week of April 5, 2021. CSR and Sustainability news for Gilead Sciences, Inc., Biotechnology and USA. Gilead Sciences Inc. (NASDAQ:GILD) went up by 1.43% from its latest closing price compared to the recent 1-year high of $79.31. Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest health-care deal on record. Gilead Sciences Inc. [NASDAQ: GILD] loss -0.87% on the last trading session, reaching $68.75 price per share at the time. Get the latest Gilead Sciences, Inc. (GILD) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Jun 9, 2021 at 2:10 PM EDT. Die Aktie notiert derzeit mit 67.45 USD beinahe unverändert (+0.04 Prozent). Gilead Sciences at Jeffries Virtual Healthcare Conference. Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. Gilead Sciences (GILD) cut its losses on a rheumatoid arthritis treatment in partnership with Galapagos (GLPG), sending GLPG stock tumbling on Wednesday. Nasdaq 100. News items for the week of April 5, 2021. "Remdesivir works at the Five questions to Gilead Sciences regarding the recent developments in the FIP community regarding treatment with unregulated substances derived from Gilead's GS-441524. Latest news headlines for Gilead Sciences Inc with market analysis and analyst commentary. Gilead Sciences Inc. had a pretty Dodgy run when it comes to the market performance. The company report on June 4, 2021 that Kite’s Tecartus® Demonstrates High Response Rate in Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Earning Priority Review Designation. Gilead currently pays a quarterly dividend of $0.71, which is higher than the $0.68 it was paying last year. Gilead Sciences, Inc GILD closed up over 1% to $66.03 on Wednesday to the tune of 6.57 million shares. Shares of the big biotech have instead jumped 20% so far this year, putting Gilead in an elite group of stocks in positive territory in 2020. (GILD) Nasdaq Listed. TOKYO, Apr 23, 2021 - (JCN Newswire) - Gilead Sciences K.K. Nachrichten zur GILEAD SCIENCES Aktie - schnell & kompetent - Aktuelle TOP-Meldung: Gilead Sciences hat die Zahlen zum jüngsten Quartal vorgelegt Gilead Sciences Aktie News aktualisieren Specials: Webinare Gilead Sciences News Werbung Weiter aufwärts? Headline. Tokyo, April 23, 2021 – Gilead Sciences K.K. Its lead candidate is entospletinib, a SYK inhibitor acquired as part of a deal with Gilead Sciences last month, under development for patients with … The day’s price range saw the stock hit a low of $67.11, while the highest price level was $67.9644. Gilead Sciences at Goldman Sachs Annual Global Healthcare Conference. gilead sciences Blogs, Comments and Archive News on Economictimes.com India approaches Egypt, UAE 4:00a Barron's What's Driving the AMC Trade? Get the latest Gilead Sciences, Inc. (GILD) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Gilead Sciences at Bernstein Annual Strategic Decisions Conference. View analysts' price targets for Gilead Sciences … appears to be modestly undervalued, according to GuruFocus Value calculation. Gilead Sciences Aktie News aktualisieren Specials: Webinare Gilead Sciences News Werbung Weiter aufwärts? Environment 59 Employees 60 Community 59 Governance 53. The positive news …
Metall Blech Englisch,
Wird Der Sonnenuntergang Heute Schön,
Fifa 21 Apk Obb Highly Compressed,
Susan Miller Horoskop Deutsch,
Bruschetta Frischkäse Rezept,
Mtd Rasentraktor Black Edition Zubehör,
Gabriella Von Monaco 2021,
Außenpolitik Sowjetunion Nach 1945,
Inga Lindström Das Haus Am See Darsteller,
Commentaires récents